Syntax Bio, a synthetic biology company programming the next generation of cell therapies, today announced the publication of new research in Science Advances detailing the company's CRISPR-based ...

The European Patent Office (EPO) upholds bit.bio's patent for its dual genomic safe harbour technology, opti-ox™, securing the broadest possible claims for programming of pluripotent stem cells (PSCs) ...

Syntax Bio, a synthetic biology company programming the next generation of cell therapies, has published new research in Science Advances detailing the company's CRISPR-based Cellgorithm technology, ...

Using mathematical analysis of patterns of human and animal cell behavior, scientists say they have developed a computer program that mimics the behavior of such cells in any part of the body. Led by ...

Master's students in our Stem Cell Program perform cutting edge translational research in the field of regenerative medicine. The intention of this site is to provide a platform for our graduate ...

CAMBRIDGE, England--(BUSINESS WIRE)--bit.bio, the company coding human cells for novel cures and a pioneer in synthetic biology, today announces the successful defence of its foundational European ...